Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 48Rectal Neoplasms 29Stomach Neoplasms 24Colorectal Neoplasms 24Triple Negative Breast Neoplasms 18Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Colonic Neoplasms 10Locally Advanced Rectal Cancer 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Brain Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Pancreatic Neoplasms 4Neoplasms 4Gastrointestinal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroendocrine Tumors 3HER2-positive Breast Cancer 3Cholangiocarcinoma 3Advanced Solid Tumors 3Recurrence 2Neoplasm, Residual 2Meningeal Neoplasms 2Locally Advanced Colorectal Cancer 2Esophageal Squamous Cell Carcinoma 2Early Low Rectal Cancer 2Colorectal Cancer Metastatic 2

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Inoperable Locally Advanced HER2-Negative Breast Cancer × Capecitabine × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡